Novocure Limited Revenue Growth Rates (NVCR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Novocure Limited  (NASDAQ: NVCR)
 

NVCR's Revenue Growth by Quarter and Year

Novocure Limited's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NVCR/growth
https://api.csimarket.com/api/v1/companies/NVCR/fundamentals
https://api.csimarket.com/api/v1/companies/NVCR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NVCR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 193.40
2nd Quarter June 183.58
1st Quarter March 174.06
FY 551.04

NVCRs Annual Revenue
Novocure Limited's Revenue in the fiscal year 2025 $ 655.35 millions
Novocure Limited's Revenue in the fiscal year 2024 $ 605.22 millions
Novocure Limited's Revenue in the fiscal year 2023 $ 509.34 millions
Novocure Limited's Revenue in the fiscal year 2022 $ 537.84 millions
Novocure Limited's Revenue in the fiscal year 2021 $ 535.03 millions




NVCR Revenue third quarter 2026 Y/Y Growth Comment
Novocure Limited reported Revenue increase of 15.67% year on year in the third quarter 2026, to $ 193.40 millions, this is lower than Novocure Limited's recent average Revenue rise of 43.28%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 70 other companies have achieved higher Revenue growth. While Novocure Limited' s Revenue growth of 15.67% ranks overall at the positon no. 1266 in the third quarter 2026.


NVCR Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 15.67 %
2nd Quarter June 15.6 %
1st Quarter March 12.3 %
FY   -

Financial Statements
Novocure Limited's third quarter 2026 Revenue $ 193.40 millions NVCR's Income Statement
Novocure Limited's third quarter 2025 Revenue $ 167.20 millions Quarterly NVCR's Income Statement


NVCR Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.35 %
2nd Quarter June 5.47 %
1st Quarter March -0.17 %
FY (Year on Year)   -


Back to NVCR Growth rate Comparisons >> Back to NVCR Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #71
Healthcare Sector #227
Overall #1266

Revenue Y/Y Growth Statistics
High Average Low
173.87 % 43.28 % -11.17 %
(Jun 30 2017)  
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #71
Healthcare Sector #227
Overall #1266
Revenue Y/Y Growth Statistics
High Average Low
173.87 % 43.28 % -11.17 %
(Jun 30 2017)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Novocure Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
39.53 % 8.85 % -7.01 %
(Dec 31 2016)  


NVCR's III. Quarter Q/Q Revenue Comment
Novocure Limited achieved in the III. Quarter 2026 below company average Revenue increase of 5.35% quarter on quarter, to $ 193.40 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 5.28% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Novocure Limited's Revenue growth quarter on quarter, overall rank is 1063.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #41
Healthcare Sector #153
Overall #1063
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #41
Healthcare Sector #153
Overall #1063
Revenue Q/Q Growth Statistics
High Average Low
39.53 % 8.85 % -7.01 %
(Dec 31 2016)  


NVCR's III. Quarter Q/Q Revenue Comment
Novocure Limited achieved in the III. Quarter 2026 below company average Revenue increase of 5.35% quarter on quarter, to $ 193.40 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 5.28% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Novocure Limited's Revenue growth quarter on quarter, overall rank is 1063.


Novocure Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 725.39
Y / Y Revenue Growth (TTM) 12.94 %
Year on Year Revenue Growth Overall Ranking # 1039
Seqeuential Revenue Change (TTM) 3.75 %
Seq. Revenue Growth (TTM) Overall Ranking # 2330


Cumulative Revenue growth Comment
Although Novocure Limited's Annual Revenue growth year on year were below company's average 38.65% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 12.94% year on year, from 10.95% in Jun 30 2026.

In the Healthcare sector 204 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 842 to 1039.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 124
Healthcare Sector # 205
Overall # 1039

Revenue TTM Y/Y Growth Statistics
High Average Low
304.15 %
 38.65 %
-7.12 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 339
S&P 500 # 2330
Cumulative Revenue growth Comment
Although Novocure Limited's Annual Revenue growth year on year were below company's average 38.65% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 12.94% year on year, from 10.95% in Jun 30 2026.

In the Healthcare sector 204 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 842 to 1039.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 124
Healthcare Sector # 205
Overall # 1039

Revenue TTM Y/Y Growth Statistics
High Average Low
304.15 %
38.65 %
-7.12 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 339
S&P 500 # 2330




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NVCR's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
Rockwell Medical inc 25.21%$ 25.210 millions
Intelligent Bio Solutions Inc 25.19%$ 25.188 millions
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions


About Novocure Limited Revenue Growth Rates (NVCR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Novocure Ltd (CIK 1645113).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001645113-26-000080
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Novocure Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.